Ownership and insider activity for Immutep Limited (IMMP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Price
| Price | $0.33 |
| Market Cap | $48M |
| Exchange | NASDAQ |
| Country | AU |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-18 | Boyce Elisabeth Amanda | |||
| 2028-12-01 | Boyce Elisabeth Amanda | 295,985 | ||
| 2026-03-18 | Voigt Marc | |||
| 2026-03-18 | Voigt Marc | |||
| 2026-03-18 | Voigt Marc | |||
| 2028-12-01 | Voigt Marc | 1,200,000 | ||
| 2026-03-18 | Miller Deanne Diem | |||
| 2028-12-01 | Miller Deanne Diem | 600,000 | ||
| 2026-03-18 | Meyers Pete A. | |||
| 2029-12-01 | Meyers Pete A. | 650,000 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.2M | $23.5M | $16.6M | $26.3M | $60.1M | $80.0M | $123.4M | $161.8M | $67.4M | $68.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $20.1M | $62.3M | 0 |
| Receivables | $2.2M | $3.5M | $5.2M | $3.4M | $6.1M | $8.4M | $8.0M | $7.6M | $7460 | $9.6M |
| Inventory | $641998 | 0 | 0 | 0 | -$5.7M | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $15.9M | $28.6M | $23.5M | $31.2M | $68.4M | $90.8M | $135.0M | $191.4M | $149.1M | $80.6M |
| Property, Plant & Equipment | $24202 | $26449 | $52950 | $250571 | $309704 | $308080 | $468513 | $679723 | $569481 | $1.1M |
| Goodwill | $109962 | $109962 | $109962 | $109962 | $109962 | $109962 | $109962 | $109962 | $109962 | $109967 |
| Intangible Assets | $18.9M | $18.2M | $16.8M | $15.1M | $12.7M | $10.4M | $9.4M | $8.1M | $7.1M | $1.4M |
| Total Assets | $35.0M | $47.0M | $40.5M | $46.6M | $82.0M | $102.2M | $147.4M | $201.6M | $157.0M | $83.3M |
| Accounts Payable | $1.1M | $1.6M | $2.6M | $1.6M | $1.8M | $2.9M | $5.4M | $3.8M | $5.5M | $5.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | $208194 | 0 | 0 | 0 | $1.1M | $290165 |
| Total Current Liabilities | $2.6M | $3.9M | $5.3M | $3.4M | $5.3M | $6.4M | $9.8M | $10.5M | $12.8M | $14.2M |
| Long-term Debt | $5.8M | $6.6M | $7.6M | $8.8M | $2.5M | $1.5M | $835446 | $960763 | 0 | 0 |
| Total Liabilities | $8.4M | $13.5M | $16.2M | $13.3M | $8.8M | $8.1M | $11.0M | $12.1M | $13.3M | $21.7M |
| Retained Earnings | -$231.8M | -$244.6M | -$262.2M | -$275.7M | -$274.6M | -$302.3M | -$339.9M | -$382.6M | -$444.1M | -$520.8M |
| Total Equity | $26.5M | $33.5M | $24.4M | $33.3M | $73.3M | $94.1M | $136.5M | $189.5M | $143.6M | $61.5M |
| Total Debt | $5.8M | $6.6M | $7.6M | $9.1M | $2.8M | $1.7M | $1.2M | $1.6M | $1.6M | $1.0M |
| Net Debt | -$6.5M | -$16.8M | -$8.9M | -$17.3M | -$57.3M | -$78.3M | -$122.2M | -$180.3M | -$128.1M | -$67.8M |
| Working Capital | $13.3M | $24.8M | $18.2M | $27.8M | $63.1M | $84.4M | $125.2M | $180.9M | $136.3M | $66.5M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 5.69 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 10.76 |
Profitability
| Return on Equity | -126.06% |
| Return on Invested Capital | -118.22% |
| Return on Assets | -93.15% |
| Gross Margin | 84.97% |
| Operating Margin | -597.44% |
| Net Margin | -544.79% |
Related companies: ACHV · ALLO · CABA · CADL · CAPR · EDIT · MREO
Explore sector: Healthcare · Biotechnology
More sections of IMMP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks